1.Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel – a phase II study. Barbara Fazeny, Udo Zifko, Siegfried Meryn, Heinz Huber, Wolfgang Grisold, Christian Dittrich. Cancer Chemother Pharmacol 39: 150-156, 1996 IF: 2.170
2. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer – results of a pilot study and review of the literature. B. Fazeny, M. Baur, M. Prohaska, M. Hudec, M. Kremnitzer, S. Meryn, H. Huber, T. Grunt, A. Tuchmann, C. Dittrich. J Cancer Res Clin Oncol 127: 45-52, 1997 IF: 2.194
3. Gastric cancer as an essential differential diagnosis of minor epigastric discomfort during pregnancy. Barbara Fazeny and Christine Marosi. Acta Obstet Gynecol Scand 77:469-471, 1998 IF: 1.209
4. Recurrent cardiac tamponade as first manifestation of gastric cancer. Barbara Fazeny, Susan Meghdadi, Clemens Dejaco, Johannes Kastner, Christine Marosi, Herwig Schmidinger. Eur J Gastroenterol Hepatol 10:621- 622, 1998 IF: 1.580
5. Einwilligung und Aufklärungspflicht in der Onkologie – Übersicht über die Österreichische und Deutsche Judikatur. Barbara Fazeny, Manfred Muhm, Andrea Berzlanovich, Christoph Zielinski, Christine Marosi. Wien Klin Wochenschr112/2:92-99, 2000 IF: 0.646
6. Schmerztherapie im Lichte rezenter Gesetzesnovellierungen und deren praktische Konsequenzen. Barbara Fazeny, Manfred Muhm, Andrea Berzlanovich, Catharina Wenzel, Hartmut Hagmeister, Christine Marosi. Wien Klin Wochenschr 112/8: 372-375, 2000 IF: 0.646
7. Barriers to cancer pain management. Barbara Fazeny, Manfred Muhm, Irene Hauser, Catharina Wenzel, Peter Mares, Andrea Berzlanovich, Hartmut Hagmeister, Christine Marosi. Wien Klin Wochenschr 112/22:987-981, 2000IF: 0.646
8. Multimodal therapy of high-grade gliomas in adult. Barbara Fazeny-Dörner, Maria Piribauer, Christine Marosi. Onkologie 24(4):376-379, 2001 IF: 0.573
9. Alterations in intestinal permeability following the intensified polychemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). Barbara Fazeny-Dörner, Mario Veitl, Cahtarina Wenzel, Thomas Brodowicz, Christoph Zielinski, Manfred Muhm, Harald Vogelsang, Chrsitine Marosi. Cancer Chemother Pharmacol 49:294-298;2002 IF: 2.170
10. Maligne Hirntumore: Inhärente Chemoresistenz, Blut-Hirn-Schranke als Barriere für Zytostatika. Barbara Dörner-Fazeny, Maria Piribauer, Christine Marosi. Universum Innere Medizin 03/2002
11. Central venous catheter pinch-off and fracture: Recognition, prevention and mangement. Barbara Fazeny-Dörner, Catharina Wenzel, Andrea Berzlanovich, Gere Sunder-Plassmann, Hilde Greinix, Christine Marosi, Manfred Muhm. Bone Marrow Transplant 2003 IF: 2.554
12. Prognostic factors and survival in patients with unrsectable glioblastoma multiforme. Barbara Fazeny-Dörner, Mario Veitl, Catharina Wenzel, Maria Piribauer, Karl Rössler, Karl Ungersböck, Karin Dieckmann, Christine Marosi. Anti-Cancer Drugs 14(4): 305-312, 2003 IF: 1.506
13. Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. Barbara Fazeny-Dörner, Mario Veitl, Catharina Wenzel, Karl Rössler, Karl Ungersböck, Karin Dieckmann, Maria Piribauer, Christine Marosi. Br J Cancer 88:496-501, 2003 IF: 3.942
14. Cytogenetic and CGH findings in 4 cases of breat cancer after neoadjuvant therapy. Barbara Fazeny-Dörner, Maria Piribauer, Catharina Wenzel, C. Pirker, W. Berger, Roland Sedivy, M. Rudas, Ichi Okamoto, Christine Marosi. Gancer Genetics Cytogenetics 2003 IF: 1.529
15. Second-line Chemotherapy with dacarbacine (D) and fotemustine (F) in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Barbara Fazeny-Dörner, Mario Veitl, Karl Rössler, Monika Killer, Karl Ungersböck, Karin Dieckmann, Christine Marosi. Anti-Cancer-Drugs 2003 IF: 1.506
16. Survival improvement of patients with glioblastoma multiforme during the last 20 years in a single tertiary care center. Barbara Fazeny-Dörner, Anwar Gyries, Karl Rössler, Karl Ungersböck, Thomas Czech, Monika Killer, Karin Dieckmann, Maria Piribauer, Gerhart Baumgartner, Daniela Prayer, Manfred Muhm, Christine Marosi. Wien Klin Wochenschr 2003 IF: 0.646
1. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma. Christian Dittrich, Paul Sevelda, Martina Baur, Christian Marth, Marcus Hudec, Norbert Vavra, Thomas Grunt, Barbara Fazeny, Heinrich Salzer. Cancer 1993;71:3082-90 IF: 3.909
2. Modulation of the immunophenotype of ovarian cancer cells by N,N- dimethylformamide and transforming growth factor-ß1-A model to assess induction of tumor differentiation in vitro. Grunt ThW, Oeller H, Somay C, Dittrich E, Fazeny B, Mannhalter C, Dittrich Ch. J Cell Physiol 156:358- 366;1993 IF: 4.285
3. Etoposide and carboplatin as salvage and first line therapy in ovarian cancer patients. Dittrich C, Baur M, Vavra N, Hudec M, Fazeny B, Barrada M, Salzer H, Sevelda P. Ann Oncol 4:697-699,1993 IF: 3.153
4. Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. Harant H, Korschineck I, Krupitza G, Fazeny B, Dittrich Ch, Grunt ThW. Br J Cancer 68:530-536, 1993 IF: 3.942
5. Hochdosiertes Epirubicin (HD-EPI) in Kombination mit hochdosiertem Ifosfamid (HD-IFO) plus Granulocyte-colony stimulating factor (G-CSF) bei Patientinnen mit fortgeschrittenem Platin-vorbehandelten Ovarialcarcinom – Phase I-II Studie. Küffer E., Fazeny B., Speiser P., Kurz Ch., Vavra N., Sevelda P., Dittrich Ch. Gynäkol.Geburtshilfliche Rundsch 33 (Suppl.1),1993,296-298 IF: 0.228
6. Amonafide as First-line Chemotherapy for Metastatic Breast Cancer. G.Kornek, M.Raderer, D.Depisch, K.Haider, B.Fazeny, C.Dittrich and W.Scheithauer. Eur J Cancer 30A,1994,398-400 IF: 3.460
7. Vinorelbine after paclitaxel in breast cancer: Cross resistance and cumulative neurotoxicity? C. Dittrich, U. Zifko, B. Fazeny, M. Fiegl, W. Grisold and H. Huber. Ann Oncol 5:473-474,1994 (Letter to the editor) IF: 3.153
8. Impaired hemorheology in patients with postmastectomy lymphedema. Manuela P. Djavanmard, Ilse Michl, M. Korpan, Barbara Fazeny, Alexandra C. Budinsky, Elmar Wiesinger, Georg Weinländer, Michael Binder, Margot Püspök, Christoph C. Zielinski, Veronika Fialka, Renate Koppensteiner and Christine Marosi. Breast Cancer Res Tr 1996,38:283-288 IF: 2.866
9. Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells. Flicker SH, Schneider SM, Offterdinger M, Dittrich E, Fazeny B, Valenta R, Huber H, Dittrich C, Grunt TW. Cancer Lett 115(1):63-72, 1997 IF: 1.741
10. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgastrim versus CEOP/IMVP-Dexa alternating chemotherapy aggressive non-Hodgkin’s Lymphoma (NHL). A multicenter trial of the Austrian Working Group for medical tumor therapy. M.A. Fridrik, R. Greil, H. Hausmanninger, O. Krieger, P. Oppitz, M. Stöger, J. Klocker, M. Neubeuer, W. Helm, J.Pont, B.Fazeny, M. Hudec, I. Simonitsch, T. Radaszkiewicz. Ann Hematol 75(4):135-140, 1997 IF: 1.566
11. Cytogenetic analysis and fluorescence in situ hybridization in a case of IgD multiple myeloma. Weinlaender G, Drach J, Raderer M, Okamoto I, Ackermann J, Stoegermayer B, Fazeny B, Nowotny H, Marosi C. Cancer Genet Cytogenet 105(2):172-176, 1998 IF: 1.529
12. Does 99mTc-Sestamibi in brain tumours reflect blood brain barrier damage only ? Staudenherz Anton, Fazeny Barbara, Nasel Christian, Killer Monika, Ungersböck Karl, Marosi Christine, Koechel Holmer, Puig Stefan, Leitha Thomas. Neuroimage 12(1):109-111, 2000 IF: 7.879
13. Karyotypic findings in two cases of male breast cancer. Rudas M, Schmidinger M, Wenzel C, Okamaoto I, Budinsky, A, Fazeny B, Marosi C. Cancer Genet Cytogenet 121(2):190-193, 2000 IF: 1.529
14. Feasibility and toxicity of CCNU-therapy in elderly patients with GBM. Maria Piribauer, Barbara Fazeny-Dörner, Karl Rössler, Karl Ungersböck, Thomas Czech, Monika Killer, Karin Dieckmann, Peter Birner, Daniela Prayer, Johannes Hainfellner, Manfred Muhm, Christine Marosi. Anti-Cancer Drugs 14(2): 137-143, 2003 IF: 1.506
15. Sudden natural death in the oldest old (>85 years) – an autopsy study of 1886 patients. Andrea Berzlanovich, Johann Missliwetz, Ernst Sim, Barbara Fazeny-Dörner, Peter Fasching, Christine Marosi, Thomas Waldhoer, Manfred Muhm. Am J Med 114 (5): 365-369, 2003 IF: 6.106
16. Psychometric and Quality-of-life assessment in long-term glioblastoma survivors. M. Schmidinger, L. Linzmayer, A. Becherer, B. Fazeny-Dörner, D. Prayer, M. Killer, K. Ungersböck, K. Dieckmann, Ch. Zielinski, Ch. Marosi. J Neuro-Oncol 2003 (in press) IF: 1.435
17. Berzlanovich A, Keil W, Waldhoer T, Sim E, Fasching P, Fazeny-Dörner B. Do centenarians die healthy? An autopsy study. J Gerontol A-Biol 2005; IF: 4.369
18. Berzlanovich A, Fazeny-Dörner B, Waldhoer T, Fasching P, Keil W. Death at lunch: foreign body asphyxiation – a preventable cause of death in the elderly? Am J Prev Med 2005;28(1):65-69. IF: 3.256
19. Berzlanovich A, Fazeny-Dörner B, Veitl M, Fasching P, Keil W. Cardiovaskuläre Todesursachen bei Typ-2-Diabetikern (> 85 Jahre) Euro J Ger 2005. (invited paper)
1. „Medikamentöse Schmerztherapie in der Onkologie“. Barbara Fazeny und Christian Dittrich. In:“Klinische Onkologie“ 1. Auflage; Prof. Huber, Prof.Hiddemann, Prof. Bartram (Hsg.), Springer Verlag Heidelberg
2. “Der Wunsch nach assistiertem Selbstmord bei unheilbaren Krebspatienten – Eine Standortbestimmung der Hauptursachen für die zunehmende Diskussionen“. Barbara Fazeny und Heinz Huber. In: Leben – Sterben – Euthanasie? Prof. Bonelli, Prof. Prat (Hrsg.) 2000; 97-102; Springer Wien New York
1. „Insulin und C-Peptid – postmortale Diagnostik“. Manfred Muhm, Barbara Fazeny, Andrea Berzlanovich, G. Bauer. In: Az igazságügyi orvosok 6. Alpok- Adria-Pannónia, találkozójának különkiadása, 1997; 70-72; L. Nagy (Ed.) Veszprémi Nyomda RT
2. „Insulin-Intoxikation als Suizid und in Tötungsabsicht“. M.Muhm, A.Berzlanovich, D.Seidler, B.Fazeny, G.Bauer. In:Az igazságügyi orvosok 6. Alpok-Adria-Pannónia, találkozójának különkiadása, 1997; 162-164; L. Nagy (Ed.) Veszprémi Nyomda RT
3. „Lesch-Nyhan Syndrom – Forensische Aspekte einer seltenen Erkrankung“. A.Berzlanovich, M.Muhm, H.Budka, M.Kraupp, B.Fazeny, G.Bauer. In:Az igazságügyi orvosok 6. Alpok-Adria-Pannónia, találkozójának különkiadása, 1997; 140-142; L. Nagy (Ed.) Veszprémi Nyomda RT
4. Mitwirkung am „Final Report of the Expert Group Meeting on DDDs of narcotic drugs” des International Narcotic Control Boards der Vereinten Nationen. Vienna 2.-4. Dezember 2002